BWX Technologies Sharpens Nuclear Focus With Medical Divestiture as Commercial Backlog Signals Multi-Decade Super Cycle
Q2 2026 earnings call held August 3, 2026; company raises full-year guidance and confirms sale of medical business to Nordic Capital
BWX Technologies used its second-quarter print to make one of the more significant strategic moves in its recent history, agreeing to sell roughly 80% of its medical and Kinectrics stable isotope businesses to Nordic Capital in a deal worth up to $800 million. The transaction, structured as $750 million in guaranteed consideration plus shared economics that could push the total higher, removes a business that represented only 3% of total sales but consumed disproportionate management attention. CEO Rex Geveden was blunt about the rationale: "That asset wasn't for sale. We certainly weren't going through strategic considerations there. We were approached by the buyer, and they came forward with a very compelling offer financially." He added that the company "can't shoot at everything that moves," framing the sale as a resource-allocation decision rather than a retreat from nuclear medicine, a market BWXT still believes in enough to retain a 20% equity stake.
CFO Michael Fitzgerald quantified the businesses being sold at approximately $130 million of 2026 revenue, at a margin modestly accretive to the Commercial Operations segment average, with the company shifting to equity-method accounting on its retained stake and no associated revenue going forward. Management was noncommittal on use of proceeds beyond funding its 6% to 7% of sales capital expenditure program and maintaining "a fine filter" on its M&A pipeline, though Fitzgerald noted upcoming bond maturities as a potential use of capital.
Commercial Manufacturing Buildout Accelerates Post-PCG Close
The completed acquisition of Precision Components Group in early July is reshaping BWXT's expansion plans faster than expected. While PCG's current backlog skews toward naval nuclear propulsion, Geveden said the deal "establishes an important commercial manufacturing platform" and has opened up East Coast site options that could leverage PCG's existing real estate and workforce, potentially accelerating time to market versus the previously discussed Mount Vernon, Indiana location. Whichever site is ultimately chosen will require deepwater port access to ship large components like steam generators and reactor pressure vessels globally, complementing PCG's medium-component capabilities. Geveden was explicit that site selection, not capital availability, is the remaining gating factor: "There's nothing that's stalling this out. It's just a matter of site selection at this point, and we'll get to that decision in a pretty short order." The company also received a $21 million DOE award tied to domestic manufacturing capacity and expects a final investment decision within months.
On competitive positioning against legacy Vogtle-era suppliers, Geveden argued BWXT now holds structural advantages few rivals can match: "We certainly have the largest component nuclear manufacturing plant in North America, really the only surviving one. And when we're done with our capacity expansion in Cambridge, we will have the world's largest nuclear clean room." PCG cannot produce the very largest components such as AP1000 reactor pressure vessels, but fills out mid-scale capability including fuel assemblies and pressure boundary components.
Guidance Raised Across the Board, But Commercial Margins Take a Near-Term Hit
Second-quarter revenue rose 18% year-over-year to $902 million, including 9% organic growth, while adjusted EBITDA increased 7% to $156 million and adjusted EPS rose 5% to $1.07. Full-year revenue guidance now sits at approximately $3.8 billion, with adjusted EBITDA guidance raised $10 million at the midpoint to $662 million-$672 million, and EPS guidance moving to $4.70-$4.80. Free cash flow guidance was lifted by $30 million to $345 million-$360 million.
The segment-level guidance revisions tell a more nuanced story. Government Operations revenue growth expectations were trimmed to high single digits from low teens previously, but this reflects favorable cost performance under BWXT's accounting rules that lowers reported revenue while improving margins — adjusted EBITDA margin guidance for the segment was raised to approximately 20.5% from greater than 19%. Commercial Operations tells the opposite story: revenue growth guidance was raised sharply to approximately 45% from approximately 30%, with slightly more than half of the increase from PCG and the rest from stronger organic commercial power demand, but margin guidance was cut to approximately 13% from approximately 14% as the company absorbs investment costs tied to U.S. capacity expansion and executive hiring ahead of anticipated growth. Fitzgerald indicated margins should expand more meaningfully in 2027.
Backlog and Order Pipeline Point to Imminent New Nuclear Wins
Backlog stood at $8.4 billion, up 40% year-over-year, with a trailing 12-month book-to-bill ratio of 1.7 times. Geveden said the company believes there is "a credible opportunity to secure at least one new build nuclear equipment order before year-end," pointing to active quoting activity across three additional SMRs at the Darlington site, AP1000 opportunities, and X300 opportunities in the U.S. He described recent conversations with GE Vernova leadership in Budapest as encouraging and characterized industry players as "biased to action."
On why Westinghouse has yet to land a firm U.S. AP1000 order despite favorable federal support, Geveden offered a specific explanation tied to deal structure: the first tranches of X300 and AP1000 orders are being organized as special purpose vehicles in which the U.S. government and other participants would own the reactors outright, with utilities serving only as operators. "I think the utilities are sort of waiting to see how those deals come out before they step into it," he said, suggesting utility-driven commercial orders may lag the sovereign-backed government deals rather than move in parallel.
Navy Shipbuilding Plan Shift Smooths a Historically Lumpy Business
The Navy's updated 30-year shipbuilding plan, released in May, calls for sustained annual production of two Virginia-class submarines and one Columbia-class submarine, while moving Ford-class aircraft carrier procurement to a four-year cadence from the previous five-year cycle. Geveden called this shift more financially significant to BWXT than any single new program, explaining that the prior ordering cadence created periodic "gap years" where only one carrier shipset moved through the company's plants instead of two, producing what he called a "revenue bathtub." The four-year cadence eliminates that gap, meaning BWXT should have two to four shipsets in production simultaneously going forward, improving rate stability. Management indicated the financial benefit becomes visible starting around 2028, when the next wave of long-lead procurement under the new cadence begins flowing into results.
The plan also introduces a nuclear-powered battleship concept using a single Ford-class reactor, though Geveden cautioned this remains early-stage and contingent on congressional authorization, with long-lead procurement not expected before 2028.
mPower Technology Monetized Through Licensing Rather Than Direct Deployment
BWXT disclosed two agreements tied to its dormant mPower small modular reactor design, developed originally under predecessor company Babcock & Wilcox starting around 2008-2009 before being shelved in 2014 after roughly $400 million in spend, with an estimated $600 million still required to complete NRC licensing at the time. Geveden described the asset as "kind of IP that's been sitting there on the shelf... a partially designed, partially certified small modular reactor" rated at 195 megawatts. Under an exclusive land-based licensing deal with Applied Atomics, that company will fund and lead design completion and NRC certification while BWXT retains manufacturing rights, royalty rights, and underlying IP — with Geveden noting the arrangement gives BWXT "right of first refusal for manufacturing all the components." Separately, BWXT signed a feasibility study with Core Power to evaluate mPower for floating, barge-based offshore power applications. Neither deal signals a return to reactor OEM ambitions; Geveden reiterated the company's strategic choice to remain a merchant component supplier rather than compete with reactor vendors directly.
TRISO Fuel Investment Still Pending Firmer Order Visibility
BWXT's Antares Mark-0 reactor became the first advanced reactor to achieve criticality under the administration's Reforming Nuclear Reactor Testing executive order, using TRISO fuel and HALEU supplied by the company — a milestone Geveden pointed to as evidence of leadership in advanced nuclear fuels. Existing capacity in Lynchburg, Virginia produces a few hundred kilograms of TRISO fuel annually, which Geveden said was nearly fully consumed loading the Pele microreactor core over roughly 18 months, leaving only modest headroom for near-term customers like Antares. A larger commercial investment tied to the company's Kairos collaboration in Wyoming, potentially costing $300 million to $500 million split with partners and offset by a $100 million Wyoming Energy Authority grant, remains under evaluation pending firmer order visibility, particularly a pending decision on the Janus program expected later this year. "It's still a highly uncertain market, in my opinion," Geveden said, "and so we're not yet ready to make a full capital commitment on it, but it is enticing."
NNSA Enrichment Program Progressing Toward a Larger Commercial Question
The company's centrifuge manufacturing development facility, stood up just 14 months ago, remains on schedule to deliver an operational prototype centrifuge this year, while the HPDU plant construction in Jonesborough, Tennessee is expected to contribute meaningfully to Government Operations revenue growth in the second half of the year. Geveden outlined a broader opportunity in building out enrichment capability from natural or depleted uranium up through high-assay low-enriched uranium, all using U.S.-sourced, unobligated equipment as required by treaty. He flagged this as carrying uniquely higher supply chain costs, raising an open question about commercial viability on a contribution-margin basis for very large-scale plants — a nuance that adds uncertainty to what is otherwise framed as a strategically important growth vector.
Canada's New Nuclear Strategy and International Momentum
Geveden characterized Canada's newly released federal nuclear strategy, which contemplates up to 10 new large reactors by 2040 alongside CANDU life-extension work and SMR deployments already underway, as arguably placing Canada ahead of the U.S. in near-term commercial nuclear momentum given the Darlington SMR program. He estimated long-lead orders tied to the new large-reactor build-out, given multi-year advance procurement timelines, would begin influencing BWXT's business in "the early 2030s." Management also cited demand across Poland, Bulgaria, the U.K., Sweden and other European markets as reinforcing a broader secular growth thesis, alongside a $17.5 billion DOE loan commitment supporting AP1000 long-lead equipment procurement.
On execution risk, Geveden reported no material supply chain constraints on zirconium tubes or large forgings, crediting the company's naval propulsion heritage — 420 small modular reactors delivered over roughly 50 years — for maintaining supply chain muscle memory competitors lack. Labor availability was described as generally under control, with turnover in the mid-single digits, though skilled trades remain harder to find than nuclear engineers and steelworker shortages in Canada are being actively managed.